CRTH2 Antagonist Programme

Oxagen’s Lead Programme – CRTH2 antagonists for Asthma, allergy and inflammatory Disease.

Oxagen has identified a number of potent antagonists of the CRTH2 receptor which are highly selective small molecular weight compounds with a range of physical properties enabling multiple administration routes to treat a range of allergic and inflammatory diseases in man. To date preclinical activity has been demonstrated in a number of models of asthma and allergic and inflammatory diseases.
The lead molecule ODC9101 is in Phase IIa clinical studies and demonstrates safety and suitability for a once a day oral product to treat, in the first instance, asthma. Other molecules in this and other series, all covered by Oxagen’s patent estate are being developed for a range of other therapeutic indications including rhinitis, atopic dermatitis and allergic conjunctivitis.

Click here for further information on Oxagen's CRTH2 programme

CRTH2 review article published in Current Opinion in Pharmacology